'The Role of Adiponectin in Ovarian Cancer' Undergraduate Research Project Application Form.

INSTRUCTIONS - PROFESSORS: Fill out Sections A & B then submit this form online. (You will receive an email copy of the form. The Office for Undergraduate Research in Science will also post the project online, indicating whether the project is open for students to apply or taken.) DONE

INSTRUCTIONS - STUDENTS: You may receive this form by email, or you may download it after it has been posted. Either way, print this form. Complete and sign Section C on the hardcopy. Ask your supervisor to sign Section D. Take it to the department corresponding to the course number in Section A (this may or may not be your own department). Do not register for a '396' course on Minerva until you receive departmental permission. Have a discussion with your supervisor about time/work expectations, keeping in mind that this is a 3-credit course (roughly, 10 hours per week for 12 weeks). Remember that a '396' course is an elective.

INSTRUCTIONS - DEPARTMENTS: After the unit chair/director/designate approves (or not) this project, notify student. If approved, please give student permission to register on Minerva, and fax this form (with signatures) to the Office for Undergraduate Research in Science.

QUESTIONS OR FEEDBACK? Contact Victor Chisholm by email, or phone 514-398-5964.


Name: Dr. Walter H. Gotlieb

Email: walter.gotlieb [at] mcgill.ca (walter dot gotlieb at mcgill dot ca)

Phone: 340-8222 ext. 3114

Website: www.mcgill.ca/translational-research-cancer/researcher-biographies/gotlieb/

Supervisor's department: None of the above

Supervisor's department (if none of the above) Obstetrics & Gynecology and Oncology

Course number: ANAT396 (Anatomy and Cell Biology)


Term: Winter 2010-2011

Project start date: January 4, 2011

Project end date: April 8, 2011

Project title: The Role of Adiponectin in Ovarian Cancer

Project description: Background: Ovarian cancer (OC) is regarded as a particularly deadly form of cancer because it is usually diagnosed in its later stages due to the relative lack of specific signs and symptoms of the disease, as well as a lack of reliable tests for early detection. Obesity, meanwhile, has long been recognized as a risk factor for a variety of cancers, ovarian cancer included. The mechanisms underlying this relationship have become a very active area of research. Adiponectin is a complement C1q-related protein that is expressed almost exclusively in adipose tissue, and that circulates at high levels in serum. Being a key regulator of insulin sensitivity and inflammation, it is considered a link between obesity, insulin resistance, and diabetes. Adiponectin expression is negatively correlated with level of obesity, and possibly with risk of obesity-related malignancies as well, including ovarian cancer. Of particular interest to researchers is the potential role of adiponectin as a predictive marker of ovarian cancer, as well as a therapeutic target in the fight against this disease.
Rationale: The purpose of this study is to measure adiponectin levels in an ovarian cancer population to verify whether it can predict the development of OC, or whether it can be a mediator of ovarian tumorigenesis.
Objectives: 1) To characterize the expression of adiponectin in OC cell lines, and examine the effect of recombinant adiponectin on cell survival, as well as downstream signaling. 2) To determine the adiponectin levels in the serum of patients with and without OC, and establish correlations with grade and/or stage of the disease. 3) To measure the expression of adiponectin receptors (adipoR1 and adipoR2) in human ovarian tumors by immunohistochemistry (IHC), and correlate the expression with grade and/or stage of the disease.
Expected contribution to the field: Low adiponectin levels are associated with obesity and many types of cancer. Although OC is an obesity-related malignancy, there is a lack of knowledge regarding the role of adiponectin in this type of cancer. Our preliminary findings may lead to new approaches in the treatment of this cancer.

Prerequisite: 1 term completed at McGill + CGPA of 3.0 or higher; or permission of instructor.

Other prerequisite, if applicable:

Grading scheme (The final report must be worth at least 50% of final grade): 50% lab work, 50% written research report

Other project information:

Project status - This project is: Taken. The professor has no more '396' projects this term.

How students can apply: N/A; this project is filled.

If other, please specify:

Ethics, safety, and training

Which of the following, if any, is involved? None

Animal subjects [ ]

Human subjects [ ]

Biohazardous substances [ ]

Radioactive materials [ ]

Handling chemicals [ ]

Using lasers [ ]

Supervisors are responsible for the ethics and safety compliance of undergraduate students.


Do not complete this section unless/until the student is identified.


McGill ID:

Email (first.last [at] mail.mcgill.ca):


Program (E.g., B.Sc. Maj. Chem. Min. Biol.):

Level (U0 / U1 / U2 / U3):

Student signature - I have not applied for another '396' course in this term:


Do not complete this section unless/until the student is identified.

Supervisor: I give my permission for the student identified in section C to register for this project under my supervision.

Supervisor's signature:


Unit chair/director/designate: I certify that this project conforms to departmental requirements for 396 courses.

Unit chair/director/designate's name:

Unit chair/director/designate's signature: